0001415889-23-010286.txt : 20230623 0001415889-23-010286.hdr.sgml : 20230623 20230623200025 ACCESSION NUMBER: 0001415889-23-010286 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230622 FILED AS OF DATE: 20230623 DATE AS OF CHANGE: 20230623 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Trachtenberg Eric CENTRAL INDEX KEY: 0001646300 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 231039208 MAIL ADDRESS: STREET 1: 1414 RALEIGH ROAD STREET 2: SUITE 400 CITY: CHAPEL HILL STATE: NC ZIP: 27517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 4 1 form4-06232023_080613.xml X0407 4 2023-06-22 0001479419 Kala Pharmaceuticals, Inc. KALA 0001646300 Trachtenberg Eric C/O KALA PHARMACEUTICALS, INC. 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 false true false false SEE REMARKS 0 Common Stock 2023-06-22 4 A 0 37559 0 A 64693 D Stock Option (right to buy) 14.56 2023-06-22 4 A 0 50078 0 A 2033-06-21 Common Stock 50078 50078 D Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026. Includes 62,874 unvested RSUs. This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. General Counsel, Chief Compliance Officer and Secretary /s/ Eric Trachtenberg 2023-06-23